RA0713

antibody from Oursmab

Targeting: TFPI EPI, LACI, TFI, TFPI1

Western blot (Supportive data in Antibodypedia)

ELISA (Supportive data in Antibodypedia)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0713

Provider

Oursmab

Product name

Concizumab (Biosimilar Reference Antibody) (TFPI)

Antibody type

Monoclonal

Description

Concizumab is an investigational humanized monoclonal antibody developed as a novel prophylactic treatment for hemophilia A and B, regardless of inhibitor status. It represents a new class of therapy known as an anti-TFPI (tissue factor pathway inhibitor) antibody. Unlike traditional factor replacement therapies, concizumab works by modulating the body's own natural coagulation pathway to enhance thrombin generation. It is administered via subcutaneous injection, offering a significant convenience advantage over intravenous factor products. Clinical trials have demonstrated its potential to reduce bleeding episodes effectively.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Concizumab (Biosimilar Reference Antibody) (TFPI)-RA0713-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.

ELISA

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

ELISA plate pre-coated Antigen protein, can bind Concizumab (Biosimilar Reference Antibody) (TFPI)-RA0713 in a linear range of 3.91-125 ng/mL.